3 recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
| Phase 1 | 1 | Recruiting 1 |
Follow Jeeyun Lee: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer Trastuzumab deruxtecan, Capecitabine, Rilvegostomig - Stomach Neoplasms | Phase 2 | Recruiting | Jeeyun Lee | 100 | 2025-01-22 | 2026-07-01 |
| Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer Trastuzumab deruxtecan, Afatinib - Stomach Neoplasm | Phase 1 / Phase 2 | Recruiting | Jeeyun Lee | 61 | 2024-09-30 | 2025-12-15 |
| Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) Durvalumab, Savolitinib - Stomach Cancer, Adenocarcinoma | Phase 2 | Recruiting | Jeeyun Lee | 25 | 2023-01-05 | 2026-01-21 |
Stomach Neoplasms (3) · Adenocarcinoma (1)
durvalumab (2) · trastuzumab deruxtecan (2) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · Afatinib (1) · Capecitabine (1) · Oxaliplatin (1)
South Korea (3)